New medication also reduces by 40 percent the number of pulmonary exacerbations, the leading cause of death in cystic fibrosis patients
Results from two phase 3 clinical trials published today in the New England Journal of Medicine show that a new combination of medications can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation – the most common form of the life-threatening, genetic disease found in over half of the cystic fibrosis (CF) population. Approximately 8,500 people in the U.S., and 22,000 people in North America, Europe and Australia, age 12 and older with cystic fibrosis carry this gene mutation.
The international trial, which studied more than 1,000 cystic fibrosis patients age 12 and older, revealed that a combination of the drugs Kalydeco (ivacaftor) and lumacaftor, an experimental drug that has not yet been approved by the Food and Drug Administration (FDA), successfully treated the defective CF protein and improved lung function. The drugs also helped patients achieve a 40 percent reduction in pulmonary exacerbations, the leading cause of death in cystic fibrosis patients.
“Being able to treat not just the symptoms, but the underlying cause of cystic fibrosis by targeting this specific gene mutation, is a major game changer because it is by far the most common in patients with this disease,” said Dr. Bonnie Ramsey, director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute and professor of Pediatrics at the University of Washington, who presented the study’s findings at the Center for Drug Evaluation and Research advisory committee meeting on May 12. “Previously, we found that Kalydeco treated just four percent of cystic fibrosis patients, but this new combination treats the defective CF protein for a much greater number of patients.”
The drugs, which work together to address the defective gene mutation by allowing the proteins within the cell to fold properly, reach the cell surface and then work as a salt channel, were given to patients over the course of 24 weeks in an effort to gain insight on how they may improve lung function and quality of life for people living with cystic fibrosis.
The trial included cystic fibrosis patients from Seattle Children’s and the University of Washington Medical Center. Today, the median predicted age of death for a person with the disease is in the mid-20s.
“What gives me tremendous confidence and excites me the most are the comprehensive health improvements seen in patients across all age groups, in all geographies and with all levels of disease severity,” said Ramsey, who was one of four lead authors on the trial and is a pioneer in cystic fibrosis treatment. “Patients can now have longer periods of good health, greatly improving their quality of life.”
The Latest on: Cystic Fibrosis
via Google News
The Latest on: Cystic Fibrosis
- Michigan residents with rare diseases could get more state supporton November 28, 2021 at 3:15 pm
A proposed Rare Disease Advisory Council would advise the state Legislature and the governor, coordinate with other organizations and identify best practices for research and priorities.
- Young girl fighting for life in hospital amid battle with Cystic Fibrosison November 26, 2021 at 5:46 am
Indie-Rose Breckon, aged eight, is on life support in hospital after her lifelong condition of Cystic Fibrosis took a bad turn.
- 'I officially received Trikafta': Ottawa woman with cystic fibrosis receives life-saving medicationon November 25, 2021 at 6:13 pm
A 23-year-old Ottawa woman with cystic fibrosis received a life-saving medication this week, and is now vowing to continue to fight until every single CF patient has it "in their hands." ...
- Stittsville woman with cystic fibrosis receives game-changing drug after initial denialon November 25, 2021 at 4:06 pm
Unpleasant though the experience was, it told the 23-year-old Stittsville student and cystic fibrosis patient that the life-saving medication she’d started taking that day was working, expelling a ...
- MSU and Spectrum Health Partner on Promising Cystic Fibrosis Treatment Studyon November 24, 2021 at 12:43 pm
MSU and Spectrum Health in Grand Rapids are studying the effectiveness of a promising FDA approved treatment called Trikafta.
- Cystic fibrosis therapies changing landscape of nutrition, cardiometabolic healthon November 22, 2021 at 11:21 am
The use of triple therapy and other highly effective modulator therapies will likely change the landscape of nutrition and that of cardiometabolic parameters in patients with cystic fibrosis, a ...
- Airway-On-Chip Recapitulates Cystic Fibrosis Lung Conditionson November 22, 2021 at 4:00 am
First microfluidic organ-on-a-chip model of the disease could help bring much needed drugs, and personalized medicine approaches to patients.
- The fight to end cystic fibrosis relies on local chapteron November 21, 2021 at 9:00 am
Babies born with cystic fibrosis today are expected to live into their mid-40s and beyond in some cases. And a central reason why is the foundation those parents launched. “Working alongside the CF ...
- Cystic fibrosis faithfully modeled in a human Lung Airway Chipon November 19, 2021 at 10:28 am
The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In ...
- Private insurance is hurdle for Ontario patients needing ‘miracle’ Cystic Fibrosis drugon November 19, 2021 at 7:03 am
An annual price tag of $300,000 per patient puts Trikafta out of reach for a lot of families. Ontario said it would cover the drug, but some patients say there's a catch.
via Bing News